Compare Kinder Morgan Inc (KMI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Pfizer Inc — how do they compare? Kinder Morgan Inc trades at $32.49 (market cap $71.81B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.2× Kinder Morgan Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and Pfizer Inc for 158 Days on average.
| KMI | PFE | |
|---|---|---|
Market Cap | $71.81B | $158.56B |
Volume | 16,921,908 | 44,138,282 |
Sector | Energy | Health |
52-Week High | $34.31 | $29.02 |
52-Week Low | $25.84 | $23.67 |
Typical Hold Time | 150 Days | 158 Days |
Enterprise Value | $103.86B | $210.06B |
Dividend Yield | 3.66% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.25, up 1.35% with a bullish technical signal and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, posting 18% net income margin growth in 2025. Analyst consensus shows mixed sentiment with 47% buy ratings and a $37.20 price target, representing 15% upside potential. Recent news highlights the company's $6-7B growth runway from Southeast gas demand and data center expansion.
KMI offers investors stable fee-based revenue from energy infrastructure with a compelling dividend yield. The stock presents growth potential from natural gas demand trends but faces risks from energy market volatility and high debt levels. Current valuation metrics appear reasonable given the company's profitability and growth backlog, though technical indicators show some overbought conditions near-term.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
